Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euroneuro.2024.03.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First, thou shall not chronicize: The risk of untreated insomnia.
Eur Neuropsychopharmacol
June 2024
Bipolar and Depressive Disorders Unit, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, 170 Villarroel st, 12-0, 08036, Barcelona, Catalonia, Spain.
Cancer Patients' Attitudes Towards the Anti-Covid-19 Vaccine: A Collective Case Study.
Rev Recent Clin Trials
May 2024
Oncology Department, Istituto Ospedaliero Fondazione Poliambulanza, L. Bissolati 57, 25124, Brescia, Italy.
Aim: The purpose of the present study was to determine cancer patients' attitudes toward the anti-COVID-19 vaccine.
Background: Historically, the scientific community's responsibility was to investigate attitudes about vaccination. The course of COVID-19 in cancer patients makes them a high priority for vaccination.
[French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia].
Bull Cancer
July 2022
Hématologie clinique, Centre Léon Bérard, Lyon, France; Centre de Recherche de Cancérologie de Lyon, Centre Léon Bérard, Inserm U1052, Lyon, France; France Intergroupe de la leucémie myéloïde chronique Fi-LMC, Lyon, France. Electronic address:
Tyrosine kinase inhibitors targeting the BCR-ABL1 oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a majority of patients. However, tyrosine kinase inhibitors may at best chronicize rather than cure the disease thus current recommendation is to pursue treatment indefinitely. As a consequence, high quality treatment and care must integrate optimal disease control and treatment tolerability.
View Article and Find Full Text PDF[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Bull Cancer
February 2016
Hôpital européen Georges-Pompidou, service de médecine vasculaire, Inserm U970, 20, rue Leblanc, 75015 Paris, France.
Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a majority of patients. However, tyrosine kinase inhibitors may at best chronicize rather than cure the disease thus current recommendation is to pursue treatment indefinitely. As a consequence, high quality treatment and care must integrate optimal disease control and treatment tolerability.
View Article and Find Full Text PDF[Late-onset asthma].
Rev Med Suisse
November 2011
Service de pneumologie, Département de médecine, CHUV, 1011 Lausanne.
Late-onset asthma is a common disease, with characteristics that differentiate it from childhood asthma persisting in adults, including a heterogeneity of underlying mechanism, a correlation with occupational exposure and the tendency to chronicize. Inadequate perception of the disease importance and difficulties in diagnosis, due to the association to COPD, the broad differential diagnosis spectrum and an atypical clinical manifestation, make this disease entity underdiagnosed and under-treated, with consequences for morbidity and mortality. The treatment of adults with asthma follows the usual guidelines, but must take into account an occasional poor therapeutic response and the risk of side effects in polymorbid patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!